What is Centile Bio?
Centile Bio operates at the intersection of artificial intelligence and clinical neuroscience. The company has developed a sophisticated, proprietary platform that leverages machine learning and computational modeling to transform standard MRI and CT scans into actionable, quantitative brain biomarkers. By providing high-fidelity reference models, Centile Bio enables healthcare providers and pharmaceutical researchers to achieve greater precision in diagnostics and clinical trial outcomes. This technological infrastructure serves as a critical bridge between raw imaging data and clinical decision-making, positioning the firm as a key player in the digital health ecosystem.
The company's focus on quantitative neuroimaging addresses a significant gap in current diagnostic workflows, where subjective interpretation often limits the efficacy of neurological assessments. By standardizing these processes through AI-driven analytics, Centile Bio is effectively setting a new benchmark for objective brain health monitoring.
How much funding has Centile Bio raised?
Centile Bio has raised a total of $3.1M across 1 funding round:
Stock/Share Issuance
$3.1M
Stock/Share Issuance (2026): $3.1M, investors not publicly disclosed
Key Investors in Centile Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Centile Bio?
With the infusion of this major strategic investment, Centile Bio is poised to scale its enterprise-level deployment across clinical and research environments. The roadmap ahead likely involves the expansion of its computational modeling capabilities to cover a broader spectrum of neurological conditions, alongside the integration of its platform into existing hospital information systems. As the company transitions into this next phase of growth, the focus will shift toward securing regulatory milestones and deepening partnerships with global pharmaceutical entities conducting large-scale neuroscience research. This capital deployment will be instrumental in refining the platform's predictive accuracy and ensuring its scalability within high-volume clinical settings.
See full Centile Bio company page
